MT 3534
Alternative Names: MT-3534Latest Information Update: 26 Jul 2024
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 01 Jul 2024 Preclinical trials in Unspecified in Japan (IV), before July 2024
- 01 Jul 2024 Mitsubishi Tanabe Pharma Corporation plans a phase I trial for Healthy volunteers in Japan in August 2024 (IV) (NCT06482346)